Abciximab
- IVAbciximabReoproLong half-life (8-12 hours) and effect (haemostasis 72 hours)
Mechanism of Action
- Inhibits glycoprotein IIb/IIIa receptors, preventing them from binding to plasma adhesive proteins such as fibrinogen and von Willebrand factor (vWF) and facilitating platelet adhesion.
Clinical Use
Indications
- Prevention of cardiac ischaemia post percutaneous coronary intervention (with aspirin + heparin)
- Contraindications
- Active or recent internal bleeding
- Past ischaemic stroke with residual deficit
- Recent major trauma or surgery
- Intracranial neoplasm, AVM or aneurysm
- Past vasculitis
- Adverse Effects
- Bleeding
- Thrombocytopaenia
- Nausea / vomiting